Drugs and Devices

FDA approves drug to reduce CV deaths in patients with diabetes

On Dec. 2, the Food and Drug Administration (FDA) approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular (CV) death in adult patients with type 2 diabetes mellitus and cardiovascular disease. Read more


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares